Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDR
The experimentally established mechanism targets of Brivanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 16/20 | 1.00 |
| ▸ | FGFR1 known ✓ | P11362 | 5/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 1.00 |
| ▸ | FGFR4 known ✓ | P22455 | 1/20 | 1.00 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 12/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 2/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 2/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brivanib SCHEMBL1227112 | 1.00 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227111 | 1.00 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227589 | 1.00 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL14111448 | 0.92 | KDR (0.84) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL3450913 | 0.91 | KDR (0.85) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL3451591 | 0.91 | KDR (0.85) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1226392 | 0.91 | KDR (0.85) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1227534 | 0.91 | KDR (0.83) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL6471061 | 0.91 | KDR (0.83) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1226332 | 0.90 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1748 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| US-12576085-B2 | Combination comprising an ATP analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer | SAWYER MICHAEL BRUCE (CA) | 2026-03-17 | — | — | US | claimed |
| EP-3957329-B1 | COMPOSITION COMPRISING THE COMBINATION OF SOTAGLIFLOZIN AS THE SODIUM/GLUCOSE CO-TRANSPORTER 1 INHIBITOR (SGLT1) AND A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 INHIBITOR (VEGFR2) FOR USE IN TREATING CANCER | NEWISH TECH BEIJING CO LTD (CN) | 2025-11-19 | — | — | EP | claimed |
| EP-4637821-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| WO-2025216949-A1 | METHODS FOR TREATING A TUMOR WITH ANTI-CDH6 ANTIBODY DRUG CONJUGATES | ONCUSP THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250281621-A1 | GPC3 APTAMERS AND VARIANTS AND USE THEREOF | GUARDIAN THERAPEUTICS, LLC (US) | 2025-09-11 | — | — | US | claimed |
| US-12410188-B2 | Adenosine receptor antagonist | XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD. (CN) | 2025-09-09 | — | — | US | claimed |
| EP-4598523-A1 | PERK INHIBITOR HC-5404 IN COMBINATION WITH ANTI-PD-1 ANTIBODY AND/OR AN ANTIANGIOGENETIC AGENT FOR USE IN THE TREATMENT OF CANCER | Hibercell, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| US-20250249045-A1 | COMPOSITIONS AND METHODS RELATED TO EXTRACELLULAR VESICLE THERAPEUTIC DELIVERY PLATFORM | NORTH CAROLINA STATE UNIVERSITY | 2025-08-07 | — | — | US | claimed |
| WO-2022104006-A2 | GPC3 APTAMERS AND VARIANTS AND USE THEREOF | GUARDIAN THERAPEUTICS, LLC (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220152198-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND INFECTIOUS DISEASES | CEDARS-SINAI MEDICAL CENTER | 2022-05-19 | — | — | US | claimed |
| EP-3102214-B1 | COMPOSITION FOR VECTORIZING AN ANTI-CANCER AGENT | GUERBET SA (FR) | 2022-04-13 | — | — | EP | claimed |
| EP-3373932-B1 | CRYSTALLINE FORM OF A SUBSTITUTED QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3964217-A1 | USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, DIMER OR TRIMER THEREOF IN PREPARATION OF DRUG FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | claimed |
| WO-2022047189-A1 | LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-03 | — | — | WO | claimed |
| EP-3957310-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICATION FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-3957329-A1 | COMPOSITION FOR TREATING CANCER, APPLICATION THEREOF, AND DRUG | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-3755308-B1 | POROUS EMBOLIZATION MICROSPHERES COMPRISING DRUGS | VAN RIJN BEHEER B V (NL) | 2022-02-16 | — | — | EP | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576085-B2 | Combination comprising an ATP analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer | ADORA2A, ADORA2B, ABCG2 | KDR 24/4885FGFR1 594/4885FLT1 47/4885 |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | WEE1, ERBB3, ERBB2 | KDR 72/4885FGFR1 10/4885FLT1 49/4885 |
| US-12410188-B2 | Adenosine receptor antagonist | ADORA2A, ADORA2B, ADORA1 | KDR 719/4885FGFR1 1475/4885FLT1 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.